Community knowledge, satellite imagery, semi-nomadic sensitisation and outreach strategies were employed to deliver ivermectin and doxycycline treatments against onchocerciasis in a semi-nomadic population. Doxycycline was offered only when skin snip examination revealed infection.
We found that about 50% of the population has either left or joined the community within eight months; 59% of people not born in the area arrived during the last five years; 28% of those older than nine years reported never taking ivermectin; 72% (compared to 51% previously) of eligible population (≥5 years) took ivermectin; and 47% participated in skin snip test. A high proportion of participants– 15% were infected. All the infected individuals (20) were treated, and no infection was found in almost all those retested (9/10).
This study highlights a high rate of onchocerciasis and the challenges of offering continuous treatment for a prolonged period (>10 years) to a mobile population. It further demonstrates that combining ivermectin and doxycycline is preferable in a mobile population as it is curative and can be given only once.
Visit the research study page for more information.
© 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.
To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.
You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.
These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.
To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.
To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.